Wuhan Keqian Biology Co Ltd (688526) - Total Assets
Based on the latest financial reports, Wuhan Keqian Biology Co Ltd (688526) holds total assets worth CN¥4.75 Billion CNY (≈ $695.52 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Wuhan Keqian Biology Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Wuhan Keqian Biology Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 688526 market cap overview for the company's overall valuation and market capitalisation.
Wuhan Keqian Biology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Wuhan Keqian Biology Co Ltd's total assets of CN¥4.75 Billion consist of 55.0% current assets and 45.0% non-current assets. Review 688526 total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 12.1% |
| Accounts Receivable | CN¥359.69 Million | 8.0% |
| Inventory | CN¥125.60 Million | 2.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥65.10 Million | 1.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Wuhan Keqian Biology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 688526 share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wuhan Keqian Biology Co Ltd's current assets represent 55.0% of total assets in 2024, a decrease from 64.8% in 2016.
- Cash Position: Cash and equivalents constituted 12.1% of total assets in 2024, down from 45.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 8.0% of total assets.
Wuhan Keqian Biology Co Ltd Competitors by Total Assets
Key competitors of Wuhan Keqian Biology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥729.16 Million |
|
Pulike Biological Engineering
SHG:603566
|
China | CN¥3.09 Billion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $423.10 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
Wuhan Keqian Biology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.30 | 4.94 | 6.95 |
| Quick Ratio | 5.02 | 4.71 | 6.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.13 Billion | CN¥1.91 Billion | CN¥2.11 Billion |
Wuhan Keqian Biology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Wuhan Keqian Biology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.81 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -3.8% |
| Total Assets | CN¥4.50 Billion |
| Market Capitalization | $849.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values Wuhan Keqian Biology Co Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Wuhan Keqian Biology Co Ltd's assets decreased by 3.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Wuhan Keqian Biology Co Ltd (2016–2024)
The table below shows the annual total assets of Wuhan Keqian Biology Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.50 Billion ≈ $657.88 Million |
-3.76% |
| 2023-12-31 | CN¥4.67 Billion ≈ $683.55 Million |
+6.39% |
| 2022-12-31 | CN¥4.39 Billion ≈ $642.49 Million |
+17.86% |
| 2021-12-31 | CN¥3.73 Billion ≈ $545.13 Million |
+19.75% |
| 2020-12-31 | CN¥3.11 Billion ≈ $455.23 Million |
+126.83% |
| 2019-12-31 | CN¥1.37 Billion ≈ $200.69 Million |
+11.51% |
| 2018-12-31 | CN¥1.23 Billion ≈ $179.97 Million |
+31.92% |
| 2017-12-31 | CN¥932.27 Million ≈ $136.42 Million |
+57.45% |
| 2016-12-31 | CN¥592.11 Million ≈ $86.64 Million |
-- |
About Wuhan Keqian Biology Co Ltd
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. The company offers vaccines for pigs, poultry, and pets, as well as diagnostic reagents. Wuhan Keqian Biology Co.,Ltd was founded in 2001 and is based in Wuhan, China.